Research programme: arrhythmia therapeutics - Merck
Alternative Names: DPO-1Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Arrhythmias in USA
- 15 Dec 2009 Preclinical development is ongoing in USA
- 05 Sep 2007 Data presented at the 234th American Chemistry Society National Meeting (234th-ACS-2007) added to the pharmacokinetics and Arrhythmias pharmacodynamics section